NCT02882282View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2025

Conditions
Oral Cavity CarcinomaOral Intraepithelial Neoplasia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Patient Observation

Undergo observation

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02882282 - Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia | Biotech Hunter | Biotech Hunter